Medtronic's Record Q3 Earnings Boost Minnesota's Med Tech Hub

Medtronic, headquartered at 710 Medtronic Parkway in Minneapolis, reported third-quarter fiscal 2026 results on February 17, 2026, shattering expectations with worldwide revenue of $9.0 billion—a 8.7% increase as reported and 6.0% organic, the highest enterprise growth in 10 quarters.[1] Non-GAAP diluted earnings per share hit $1.36, beating analyst forecasts of $1.34 by 2 cents, while revenue topped predictions of $8.91 billion.[2] The performance builds on robust prior quarters, including Q2's $8.961 billion (up 6.6% reported) and Q1's $8.6 billion (up 8.4% reported), with the company raising full-year guidance.[4][5] Driving the surge are Medtronic's cardiovascular and diabetes segments, key to its Minnesota operations. Facilities in Fridley and Mounds View produce pacemakers, defibrillators and insulin pumps like the MiniMed series, powering double-digit diabetes revenue growth seen in recent quarters—10.3% in Q2 to $757 million and 11.5% in Q1 to $721 million.[4][5] CEO Geoff Martha highlighted during the earnings call the strongest U.S. growth since 2019, crediting innovation in these lines amid rising chronic disease rates.[2] Minnesota's medical alley, anchored by Medtronic's 30,000+ local employees, exported $10 billion in devices last year, cementing the state's status as a med-tech powerhouse. Yet investor reaction was muted: Shares fell 3.51% to $96 in pre-market trading post-earnings, lingering below the 52-week high of $106.33, possibly due to broader market concerns over future margins despite Q3 GAAP operating profit of $1.464 billion (16.2% margin).[1][2] Medtronic's momentum signals optimism for Minnesota's economy, where the firm supports thousands of jobs and fuels research at the University of Minnesota. As fiscal 2026 progresses, all eyes remain on whether this Twin Cities titan can sustain the streak.